2. Search Result
Search Result
Results for "

interferon response

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

2

Screening Libraries

4

Peptides

2

Inhibitory Antibodies

8

Natural
Products

5

Antibodies

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100564
    2',3'-cGAMP
    Maximum Cited Publications
    33 Publications Verification

    2'-3'-cyclic GMP-AMP

    		 Endogenous Metabolite STING IFNAR Metabolic Disease
    2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm .
    2',3'-cGAMP
  • HY-12512
    cGAMP
    25+ Cited Publications

    Cyclic GMP-AMP; 3',3'-cGAMP

    		 STING Inflammation/Immunology
    cGAMP (Cyclic GMP-AMP) functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators .
    cGAMP
  • HY-100564A
    2',3'-cGAMP sodium
    Maximum Cited Publications
    33 Publications Verification

    2'-3'-cyclic GMP-AMP sodium

    		 Endogenous Metabolite STING IFNAR Metabolic Disease
    2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP sodium binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP sodium is produced in mammalian cells in response to DNA in the cytoplasm .
    2',3'-cGAMP sodium
  • HY-156677
    STC-15
    4 Publications Verification

    		 METTL3 Cancer
    STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases .
    STC-15
  • HY-150741
    ODN 2216
    1 Publications Verification

    		 Toll-like Receptor (TLR) IFNAR Interleukin Related Infection Inflammation/Immunology Cancer
    ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
    ODN 2216
  • HY-156773
    STM3006
    2 Publications Verification

    		 Apoptosis METTL3 Cancer
    STM3006 is a highly potent, selective, and orally active inhibitor of METTL3 (IC50: 5 nM). STM3006 can reduce the m6A level, promote the formation of dsRNA, trigger a cell-intrinsic interferon response, and enhance the killing effect of T cells on tumors. STM3006 has anti-tumor activity, and its combination with anti-PD-1 immunotherapy yields better results .
    STM3006
  • HY-110385
    cGAMP disodium
    25+ Cited Publications

    Cyclic GMP-AMP disodium; 3',3'-cGAMP disodium

    		 STING Endogenous Metabolite Inflammation/Immunology
    cGAMP (Cyclic GMP-AMP) disodium functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP diammonium activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators .
    cGAMP disodium
  • HY-124700
    LYPLAL1-IN-1
    1 Publications Verification

    		 Cyclic GMP-AMP Synthase STING PD-1/PD-L1 Epoxide Hydrolase Metabolic Disease
    LYPLAL1-IN-1 (compound 11) is a selective, covalent, and irreversible inhibitor of the lysophospholipase-like enzyme LYPLAL1 (IC50 = 6 nM). LYPLAL1-IN-1 shows selectivity against other serine hydrolases such as carboxylesterase CES1 (IC50 > 50 μM for CES1). LYPLAL1-IN-1 inhibits the depalmitoylation function of LYPLAL1, blocking its depalmitoylation modification of cyclic GMP-AMP synthase (cGAS), thereby promoting cGAS dimerization and activation, and initiating the cGAS-STING pathway-mediated innate immune response. LYPLAL1-IN-1 can enhance DNA-induced type I interferon production, upregulate PD-L1 expression in tumor cells, and promote the accumulation of tumor-infiltrating CD8 + T cells, with the core function of strengthening the anti-tumor immune response. LYPLAL1-IN-1 is primarily used in tumor immunology research, especially in combination with PD-1/PD-L1 inhibitors .
    LYPLAL1-IN-1
  • HY-150217
    CpG ODN 10101
    2 Publications Verification

    ODN 10101

    		 Toll-like Receptor (TLR) Infection Inflammation/Immunology
    CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .
    CpG ODN 10101
  • HY-152955
    STING agonist-22
    1 Publications Verification

    		 STING Infection Inflammation/Immunology
    STING agonist-22 (CF501) is a potent non-nucleotide STING agonist. STING agonist-22 is a adjuvant by activating STING to induce the type I interferon (IFN-I) response and proinflammatory cytokine production. STING agonist-22 can be used as an adjuvant to boost the original protein vaccine, producing potent, broad, and long-term immune protection. STING agonist-22 can be used for SARS-CoV-2 variants and sarbecovirus diseases research .
    STING agonist-22
  • HY-162563
    AK59

    		STING Inflammation/Immunology Cancer
    AK59 is a STING degrader that works by leveraging HERC4, a hect domain E3 ligase. AK59 can be used in the study of autoimmune diseases and cancer .
    AK59
  • HY-Y0148
    10-Hydroxydecanoic acid

    NSC 15139; 10-HDAA

    		 Parasite Autophagy NF-κB Interleukin Related NO Synthase MDM-2/p53 TNF Receptor RANKL/RANK Caspase Infection Neurological Disease Inflammation/Immunology
    10-Hydroxydecanoic acid (10-HDAA) is a saturated fatty acid derived from 10-hydroxy-trans-2-decenoic acid, which can be isolated from royal jelly. 10-Hydroxydecanoic acid exhibits various biological activities, including anti-inflammatory, insecticidal, anti-malarial, and anti-Leishmania properties, as well as enhancing antigen-specific immune responses. The anti-inflammatory effects of 10-Hydroxydecanoic acid are primarily mediated by inhibiting the activation of NF-κB and the translation of interferon regulatory factor 1 (IRF-1), which reduces the production of interleukin 6 (IL-6) and nitric oxide (NO) in inflammatory cells. Additionally, 10-Hydroxydecanoic acid alleviates neuroinflammatory responses through the p53-autophagy pathway and the p53-NLRP3 pathway. Finally, 10-Hydroxydecanoic acid enhances antigen-specific immune responses by promoting the effective uptake of antigens by microfold cells .
    10-Hydroxydecanoic acid
  • HY-160406
    SNX281

    		STING IFNAR Interleukin Related Inflammation/Immunology Cancer
    SNX281 is a selective STING agonist, with IC50 values of 4.1, 4.5, 10.7, and 3.7 μM against human, mouse, rat, and monkey STING, respectively. SNX281 undergoes homodimerization at the STING binding site, triggering a conformational shift of STING from an inactive open state to an active closed state, thereby driving downstream STING-dependent signaling pathways. SNX281 induces type I interferons, IFN-β, TNF-α, IL-6, cytokine release, T cell responses, and long-lasting immune memory. SNX281 exhibits anti-tumor activity and is applicable to research related to colorectal cancer, melanoma, advanced solid tumors, lymphoma, and ovarian cancer .
    SNX281
  • HY-177338
    STING agonist-45

    		STING Cyclic GMP-AMP Synthase IFNAR TNF Receptor Interleukin Related Inflammation/Immunology Cancer
    STING agonist-45 is a selective STING agonist (EC50 = 0.28 μM). STING agonist-45 activates the innate immune response through the cGAS-STING pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust STING activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8 + T cell infiltration in mouse models. STING agonist-45 is promising for the study of STING-related diseases .
    STING agonist-45
  • HY-173189A
    2-5A pentasodium solution (100 mM)

    2′,5′-ApApA pentasodium; 2′,5′-trioligoadenylate pentasodium; 5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine pentasodium

    		 RSV DNA/RNA Synthesis Infection Cancer
    2-5A (2′,5′-ApApA) pentasodium solution 100 mM is a high-affinity (Ka=0.04 nM) RNase L binder. 2-5A pentasodium solution 100 mM activates the nuclease activity of latent RNase L to cleave single-stranded RNA by inducing conformational changes and dimerization of latent RNase L, thereby mediating critical antiviral responses and enhancing interferon effects. 2-5A pentasodium solution 100 mM not only effectively inhibits Rauscher murine leukemia virus replication, reduces viremia and splenomegaly, but also enhances antileukemic efficacy when combined with amphotericin B and exhibits favorable high-dose tolerance. 2-5A pentasodium solution 100 mM is an important tool molecule for investigating the pathological mechanisms of viral infection, hereditary prostate cancer and leukemia .
    2-5A pentasodium solution (100 mM)
  • HY-112951
    ChX710
    4 Publications Verification

    		 STING Cancer
    ChX710 could prime the type I interferon response to cytosolic DNA, which induces the ISRE promoter sequence, specific cellular Interferon-Stimulated Genes (ISGs), and the phosphorylation of Interferon Regulatory Factor (IRF) 3.
    ChX710
  • HY-P99744
    Modakafusp alfa

    TAK-573

    		 CD38 Inflammation/Immunology Cancer
    Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
    Modakafusp alfa
  • HY-N7781
    (-)-(E)-Guggulsterone

    (E)-Guggulsterone

    		 FXR Keap1-Nrf2 Heme Oxygenase (HO) Dengue Virus Bacterial Reactive Oxygen Species (ROS) Estrogen Receptor/ERR Cytochrome P450 Drug Metabolite Infection Metabolic Disease Endocrinology
    (-)-(E)-Guggulsterone ((E)-Guggulsterone) is an orally active natural stereoisomer of Guggulsterone (HY-107738). (-)-(E)-Guggulsterone is an antagonist for the Farnesoid X Receptor (FXR) with an IC50 of 24.06 μM and possesses potent hypolipidemic properties. (-)-(E)-Guggulsterone suppresses dengue virus (DENV) replication by upregulating antiviral interferon responses by inducing HO-1 expression via Nrf2 activation. (-)-(E)-Guggulsterone exhibits antibacterial activities against Bacillus subtilis, Staphylococcus aureus and Pseudomonas aeruginosa. (-)-(E)-Guggulsterone has cardiac protective and antioxidant activities in rats .
    (-)-(E)-Guggulsterone
  • HY-155457
    Enpp-1-IN-19

    		Phosphodiesterase (PDE) STING Cancer
    Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC50=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence .
    Enpp-1-IN-19
  • HY-P991278
    ABM-125

    		Interleukin Related Inflammation/Immunology
    ABM-125 is a IL-25 neutralizer and immune response modulator. ABM-125 neutralizes human and mouse IL-25 and blocks type 2 immune activation function. ABM-125 regulates virus-induced inflammatory cytokine expression and increases the expression level of antiviral interferons in rhinovirus-infected asthmatic bronchial epithelial cells. For the isotype control of ABM-125, refer to Human IgG1 kappa, Isotype Control (HY-P99001). ABM-125 is applicable to research related to virus-induced acute asthma exacerbations .
    ABM-125
  • HY-123291
    SM-276001

    		Toll-like Receptor (TLR) IFNAR Inflammation/Immunology Cancer
    SM-276001 is a potent selective TLR7 agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer .
    SM-276001
  • HY-B1080A
    Tilorone
    2 Publications Verification

    		 Influenza Virus Akt Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Tilorone is an orally active antiviral agent and interferon inducer that also has potential antineoplastic, immunomodulatory, and metabolic modulating effects. Tilorone induces an abnormally delayed interferon response and primarily stimulates interferon production in lymphoid tissue. Thus, Tilorone exerts antiviral effects and can be used as a chemotherapeutic agent. Tilorone has the potential to inhibit type 2 diabetes by increasing glucose uptake in vivo and in skeletal muscle cells by enhancing Akt2/AS160 signaling and glucose transporter levels .
    Tilorone
  • HY-P5522A
    TriDAP dihydrochloride
    1 Publications Verification

    L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride

    		 NOD-like Receptor (NLR) NF-κB MAP3K MEK ERK p38 MAPK Interleukin Related SARS-CoV Infection Inflammation/Immunology
    TriDAP dihydrochloride (L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride) is a NOD1 agonist with a Kd value of 34.5 μM. TriDAP dihydrochloride enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP dihydrochloride downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP dihydrochloride decreases IκBα levels and increases p65 levels. TriDAP dihydrochloride induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP dihydrochloride increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP dihydrochloride can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and SARS-CoV-2 infection .
    TriDAP dihydrochloride
  • HY-148420
    CDN-A

    		STING Inflammation/Immunology
    CDN-A is a cyclic di-nucleotide, it can be used to synthesis antibody-drug conjugate (ADC). Cyclic di-nucleotides are potent stimulators of innate and adaptive immune responses. In humans, cyclic di-nucleotide, which are either produced endogenously in response to foreign DNA or by invading bacterial pathogens, trigger the innate immune system by activating the expression of interferon genes .
    CDN-A
  • HY-110385A
    cGAMP diammonium
    25+ Cited Publications

    Cyclic GMP-AMP diammonium; 3',3'-cGAMP diammonium

    		 STING Endogenous Metabolite Inflammation/Immunology
    cGAMP (Cyclic GMP-AMP) diammonium functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP diammonium activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators .
    cGAMP diammonium
  • HY-170524
    TDI-015051

    		SARS-CoV DNA Methyltransferase Cytochrome P450 Infection
    TDI-015051 is a highly selective, orally active antiviral agent that targets the coronavirus NSP14 guanine-N7 methyltransferase. TDI-015051 binds to substrates in a non-competitive manner and forms a stable ternary complex, precisely blocking the capping and methylation processes of viral mRNA. TDI-015051 potently inhibits a variety of coronaviruses (including SARS-CoV-2 and MERS). By impairing viral replication and translation and inducing a moderate type I interferon-mediated immune response, it significantly reduces pulmonary viral load and exhibits a synergistic effect with Nirmatrelvir (HY-138687). In addition, TDI-015051 does not inhibit non-coronavirus methyltransferases, and the drug-resistant mutations it induces impair viral fitness, demonstrating excellent antiviral properties and safety. TDI-015051 can be used for research on COVID-19 and the replication mechanism of coronaviruses .The IC50 values of TDI-015051 against SARS-CoV-2, α-hCoV-NL63, α-hCoV-229E, β-hCoV-MERS are 0.15 nM, 1.7 nM, 2.6 nM and 3.6 nM, respectively, and the Ka value against SARS-CoV-2 is 0.061 nM .
    TDI-015051
  • HY-143321
    STING agonist-13

    		STING Cancer
    STING agonist-13 is a stimulator of interferon genes (STING) agonist, for cancer immunity via STING-mediated immune activation. STING agonist-13 can stimulate STING downstream signaling and promoting type I interferon immune responses. STING agonist-13 significantly decreases tumor volume and shows immunological memory-derived cancer inhibition .
    STING agonist-13
  • HY-P5522
    TriDAP

    L-Ala-γ-D-Glu-meso-diaminopimelic acid

    		 NOD-like Receptor (NLR) NF-κB MAP3K MEK ERK p38 MAPK Interleukin Related SARS-CoV Infection Inflammation/Immunology
    TriDAP (L-Ala-γ-D-Glu-meso-diaminopimelic acid) is a NOD1 agonist with a Kd value of 34.5 μM. TriDAP enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP decreases IκBα levels and increases p65 levels. TriDAP induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and SARS-CoV-2 infection .
    TriDAP
  • HY-175461
    AVI-4206

    		SARS-CoV Infection
    AVI-4206 is a selective Mac1 inhibitor with an lC50 of 64 nM. AVI-4206 reduces viral replication, restores an interferon response, and leads to a survival benefit in an animal model of SARS-CoV-2 infection. AVI-4206 can be used the study of SARS-CoV-2 infection .
    AVI-4206
  • HY-P5502
    Influenza NP (311-325)

    		Influenza Virus Others
    Influenza NP (311-325) is a biologically active peptide derived from the influenza virus nucleoprotein (NP). The NP protein is an MHC class II restricted epitope that elicits host immune responses during viral infection. Influenza NP (311-325) elicits the most potent interferon gamma (IFN-γ) production without stimulating CD8 T cells in mice.
    Influenza NP (311-325)
  • HY-176256
    endo-S-cGAFMP

    		STING Cancer
    endo-S-cGAFMP (Compound 3) is a STING agonist. endo-S-cGAFMP induces the production of interferon regulatory factors and proinflammatory cytokines by activating the cGAS-STING pathway, thereby enhancing innate and adaptive immune responses. endo-S-cGAFMP has potent immunostimulatory capacity in THP1 monocytes and RAW macrophages (EC50 values of 2.45 μM and 5.54 μM, respectively). endo-S-cGAFMP has significant antitumor activity. endo-S-cGAFMP can be used as a potential cancer immunotherapeutic agent, especially for studies of systemic administration .
    endo-S-cGAFMP
  • HY-179539
    ISR activator 3

    		Eukaryotic Initiation Factor (eIF) Neurological Disease Inflammation/Immunology
    ISR activator 3 (Compound cc81) is the active metabolite of A8. ISR activator 3 activates the integrated stress response (ISR) by binding to RIG-I (KD ≈ 0.55 μM), without inducing lipid droplet clearance. ISR activator 3 enhances the interferon response under viral mimicry signals. ISR activator 3 can be used for research on neurodegenerative diseases and immune stress .
    ISR activator 3
  • HY-174662
    Human IFNG mRNA

    		mRNA Inflammation/Immunology
    Human IFNG mRNA encodes the human interferon gamma (IFNG) protein, a member of the type II interferon class. IFNG is secreted by cells of both the innate and adaptive immune systems. The active protein is a homodimer that binds to the interferon gamma receptor which triggers a cellular response to viral and microbial infections.
    Human IFNG mRNA
  • HY-163704
    KRN7000 analog 1

    		IFNAR Interleukin Related Inflammation/Immunology Cancer
    KRN7000 analog 1 exhibits good Th1-biased immune response through induction of interferon-γ (IFN-γ) and reduction of interleukin-4 (IL-4). KRN7000 analog 1 is potential as an antitumor agent and vaccine adjuvant .
    KRN7000 analog 1
  • HY-130116A
    IACS-8779 disodium

    		STING Cancer
    IACS-8779 disodium is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy. IACS-8779 disodium shows robust activation of the STING pathway in vitro and a superior systemic anti-tumor response in the B16 murine model of melanoma .
    IACS-8779 disodium
  • HY-162861
    3-Methyl-chuangxinmycin

    		Antibiotic Bacterial Infection Inflammation/Immunology
    3-Methyl-chuangxinmycin is an antibiotic. 3-Methyl-chuangxinmycin can affect the translation process in bacteria and mammalian cells by inhibiting the enzyme that synthesizes tryptophan tRNA (TrpRS). 3-Methyl-chuangxinmycin can downregulate genes related to interferon, TNF, and inflammatory responses in RDEB_L1 cells .
    3-Methyl-chuangxinmycin
  • HY-168491
    Enpp-1-IN-25

    		Phosphodiesterase (PDE) STING PD-1/PD-L1 Cancer
    Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and low oral bioavailability. Enpp-1-IN-25 can effectively activate the intracellular STING pathway by inhibiting cGAMP degradation. Enpp-1-IN-25 can enhance immune cell infiltration in the tumor microenvironment and type I interferon responses, and potentiate the antitumor efficacy of the anti-PD-L1 antibody. Enpp-1-IN-25 can be used in the research of cancer immunotherapy .
    Enpp-1-IN-25
  • HY-Y0148R
    10-Hydroxydecanoic acid (Standard)

    NSC 15139 (Standard); 10-HDAA (Standard)

    		 Reference Standards Parasite Autophagy NF-κB Interleukin Related NO Synthase MDM-2/p53 TNF Receptor RANKL/RANK Caspase Infection Neurological Disease Inflammation/Immunology
    10-Hydroxydecanoic acid (Standard) is the analytical standard of 10-Hydroxydecanoic acid. This product is intended for research and analytical applications. 10-Hydroxydecanoic acid (10-HDAA) is a saturated fatty acid derived from 10-hydroxy-trans-2-decenoic acid, which can be isolated from royal jelly. 10-Hydroxydecanoic acid exhibits various biological activities, including anti-inflammatory, insecticidal, anti-malarial, and anti-Leishmania properties, as well as enhancing antigen-specific immune responses. The anti-inflammatory effects of 10-Hydroxydecanoic acid are primarily mediated by inhibiting the activation of NF-κB and the translation of interferon regulatory factor 1 (IRF-1), which reduces the production of interleukin 6 (IL-6) and nitric oxide (NO) in inflammatory cells. Additionally, 10-Hydroxydecanoic acid alleviates neuroinflammatory responses through the p53-autophagy pathway and the p53-NLRP3 pathway. Finally, 10-Hydroxydecanoic acid enhances antigen-specific immune responses by promoting the effective uptake of antigens by microfold cells[1][2][3][4][5].
    10-Hydroxydecanoic acid (Standard)
  • HY-N7781R
    (-)-(E)-Guggulsterone (Standard)

    (E)-Guggulsterone (Standard)

    		 Reference Standards Drug Metabolite FXR Keap1-Nrf2 Heme Oxygenase (HO) Dengue Virus Bacterial Reactive Oxygen Species (ROS) Estrogen Receptor/ERR Cytochrome P450 Infection Cardiovascular Disease Endocrinology
    (-)-(E) -guggulsterone (Standard) is the analytical standard for (-)-(E) -guggulsterone ((E)-Guggulsterone) (HY-N7781). (-)-(E)-Guggulsterone is an orally active natural stereoisomer of Guggulsterone (HY-107738). (-)-(E)-Guggulsterone is an antagonist for the Farnesoid X Receptor (FXR) with an IC50 of 24.06 μM and possesses potent hypolipidemic properties. (-)-(E)-Guggulsterone suppresses dengue virus (DENV) replication by upregulating antiviral interferon responses by inducing HO-1 expression via Nrf2 activation. (-)-(E)-Guggulsterone exhibits antibacterial activities against Bacillus subtilis, Staphylococcus aureus and Pseudomonas aeruginosa. (-)-(E)-Guggulsterone has cardiac protective and antioxidant activities in rats.
    (-)-(E)-Guggulsterone (Standard)
  • HY-130625
    PD-1/PD-L1-IN 6

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN 6 (compound A13) is a potent PD-1/PD-L1 interaction inhibitor, with an IC50 of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model .
    PD-1/PD-L1-IN 6
  • HY-181526
    Sim-9

    		IFNAR STING Inflammation/Immunology
    Sim-9 is a covalent allosteric inhibitor of interferon regulatory factor 3 (IRF3). Sim-9 binds covalently to the Cys222 residue of IRF3, induces its conformational change, blocks its interactions with TRIF, MAVS and STING, and inhibits IRF3 homodimerization and type I interferon response. Sim-9 exhibits significant anti-inflammatory, organ-protective and survival benefits in mouse models of sepsis and acute pancreatitis. Sim-9 can be used for research related to inflammatory diseases .
    Sim-9
  • HY-179524
    ISR activator 2

    		Eukaryotic Initiation Factor (eIF) Neurological Disease Cancer
    ISR activator 2 is a selective ISR activator. ISR activator 2 can preferentially activate the ISR through the binding of the cytosolic pattern recognition receptor RIG-I, which subsequently activates the heme-regulated inhibitor (HRI) ISR kinase independent of an interferon response. ISR activator 2 can be used for the study of pancreatic cancer .
    ISR activator 2
  • HY-182926
    Topoisomerase I/II-IN-9

    		DNA/RNA Synthesis Topoisomerase Cancer
    Topoisomerase I/II-IN-9 is a topoisomerase I/II inhibitor (IC50<10 μM) and a DNA damage inducer. Topoisomerase I/II-IN-9 blocks the interaction between the enzyme and DNA by binding to the DNA-binding pocket of the enzyme. Topoisomerase I/II-IN-9 activates the cGAS-STING pathway and promotes the accumulation of cytoplasmic double-stranded DNA. This further drives the production of type I interferons, CCL5, CXCL10 and interferon-stimulated genes, and induces anti-tumor immune responses in vivo. Topoisomerase I/II-IN-9 can be applied to the research of related diseases such as triple-negative breast cancer, colorectal cancer and gastric cancer .
    Topoisomerase I/II-IN-9
  • HY-181165
    SB2960

    		PKC SARS-CoV IFNAR Infection
    SB2960 is a receptor for activated protein C kinase 1 (RACK1) binder with a human KD of 5.65 μM. SB2960 can promote stress granule (SG) formation and exhibit potent antiviral activity across diverse viral species. SB2960 suppresses viral replication with minimal cytotoxicity by modulating host antiviral immune responses. SB2960 increases the thermal stability of RACK1 and reduces SARS-CoV-2 N protein levels. SB2960 enhances type I interferon (IFN-β) expression and inhibits RIG-I, ISG56, and RANTES expression. SB2960 can be used for the research of virus infection .
    SB2960

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: